106 results about "Insulin secretion" patented technology

The invention relates to an electrochemical sensor for monitoring beta cell insulin secretion in real time and a preparation method and application thereof, the sensor is an electrochemical chip modified by a multi-dimensional nano material, and the multi-dimensional nano material on the electrochemical chip is used for capturing dopamine released by beta cells; and determining the release quantity of dopamine according to the electrochemical signal. According to the method, the insulin secretion condition of the beta cells is monitored in real time by taking dopamine as a tracer agent, and the exocytosis process of the beta cells can be researched under natural and normal conditions. According to the invention, only a common Faraday cage and a basic electrochemical workstation are needed for detection, one or more beta cells can be detected, the operation is simple, and the research efficiency of insulin secretion is greatly improved. In addition, the medicine for regulating beta cell insulin secretion can be efficiently screened, and a foundation is laid for research of diabetes treatment medicine.

The invention relates to the field of microorganisms, and provides an acid-producing propionibacterium BL8 with hypoglycemic and anti-aging functions and application of the acid-producing propionibacterium BL8, the acid-producing propionibacterium BL8 is preserved in China General Microbiological Culture Collection Center on December 20, 2024, and the preservation number is CGMCC No. 33134. The acid-producing propionibacterium BL8 disclosed by the invention can be used for inhibiting the activity of DPP4, promoting insulin secretion of INS-1, and inhibiting the activity of acetylcholin esterase and excellent cellulase activity. The blood sugar can be reduced; the memory is improved, and the Alzheimer disease is prevented and relieved; and the traditional Chinese medicine composition has relatively high research and application values in the aspects of reducing blood sugar and resisting aging.

The invention relates to a heparinized gelatin / sodium alginate pancreas islet packaging material with an anti-fibrosis function as well as a preparation method and application of the heparinized gelatin / sodium alginate pancreas islet packaging material. The preparation method comprises the following steps: adding gelatin into normal saline, soaking, performing autoclaved sterilization to obtain a gelatin solution, then adding epsilon-polylysine hydrochloride into the gelatin solution, and finally adding glutamine transaminase for reaction to obtain an epsilon-polylysine grafted gelatin solution; adding heparin into the solution, and reacting to obtain a heparinized gelatin solution; adding sodium alginate and glutamine transaminase, reacting, diluting, preparing hydrogel microspheres by adopting an electrostatic spraying method, and cross-linking to obtain the hydrogel microspheres. According to the invention, heparin molecules are incorporated into a pancreas islet packaging system, so that fibrosis at the periphery of the microspheres can be relieved, the pancreas islet cells are packaged by using the pancreas islet packaging material to prepare the biological artificial pancreas, the pancreas islet cell proliferation and insulin secretion can be promoted, and the pancreas islet packaging material has a good diabetes treatment effect.

Provided is an insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by the following formula (I):wherein R1, R2 and R3 each denotes a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. An insulin secretion-promoting action of the pentadecanoic acid triglyceride at the time of elevated blood glucose level is discovered, and pharmaceuticals and health foods for improving blood glucose level and diabetes are provided using this triglyceride.

The invention relates to a leaf protein, an extraction method and application. The leaf protein extraction method comprises the following steps: pulping plant leaves to obtain a first slurry, and centrifuging to obtain a first precipitate and a first supernatant; adding water into the first precipitate, adjusting the pH value to be greater than or equal to 7, and carrying out heating treatment to obtain a first precipitate dispersion liquid; adding an organic solvent into the first precipitate dispersion liquid, and centrifuging to obtain a second precipitate and a second supernatant; respectively recovering the residual organic solvent in the second precipitate and the second supernatant to obtain a third precipitate and a third supernatant; and refining the third supernate to obtain the leaf protein. The invention also provides the leaf protein extracted by the extraction method. The invention also provides an application of the leaf protein in preparation of a product for reducing blood sugar and / or a product for improving an insulin secretion function and / or a product for improving food bulkiness. The method solves the problem that the purity, the yield and the functionality cannot be considered at the same time by the existing leaf protein extraction method.

The invention relates to the technical field of gene vectors, and discloses a multi-target multi-gene stable silencing vector and an application thereof in treating diabetes mellitus, and a multi-gene multi-target gene modification combined element is safely and efficiently integrated at a gene safety parking point of a second intron region of a CCR5 gene in a genome in a reverse fixed point manner by using a non-viral vector system; therefore, the effect of continuously silencing expression of a plurality of target genes such as MSTN, GRB10 and PTBP1 for a long time is achieved, and aging of mesenchymal stem cells cultured in vitro is remarkably inhibited. When the mesenchymal stem cells modified by the multi-target multi-gene stable silencing vector are infused, the activity is high, the chronic inflammatory microenvironment is effectively inhibited, and the senescence process is delayed; moreover, proliferation and differentiation of pancreatic beta cells are promoted, insulin secretion is enhanced, insulin resistance is effectively resisted, and diseases such as diabetes mellitus are prevented.

The main objective of this invention is to provide a novel manufacturing method capable of efficiently and directly converting or inducing somatic cells into insulin-producing cells. As an example, a method for manufacturing insulin-producing cells is provided, which involves directly differentiating and inducing insulin production from somatic cells. This method includes a step of culturing somatic cells in a serum-free differentiation-induction medium; or a step of culturing somatic cells in a differentiation-induction medium containing 5 μg / mL or more of insulin. According to this invention, insulin-producing cells with high insulin secretion capacity can be efficiently and directly manufactured from somatic cells. The insulin-producing cells obtained by this invention are useful in regenerative medicine and the like.

Disclosed herein are methods for inducing insulin secretion in a glucose-dependent manner and compounds for use in these methods.

The present invention discloses the application of Alternariol in the preparation of diabetes prevention and treatment drugs, which belongs to the field of medical technology. The present invention first screens out the compound Alternariol through in vitro DYRK1A kinase activity experiment, and its IC 50 The value was 20μM. Then, through INS-1 cell proliferation model experiments, it was found that the compound Alternariol can promote INS-1 cell proliferation and promote insulin secretion by pancreatic islet cells. Even at very low concentrations, such as 300nmol, it can significantly promote INS-1 cell proliferation. Finally, through mouse diabetes model experiments, it was further verified that the compound Alternariol can indeed control blood sugar in T1D mice and promote pancreatic proliferation in mice, while also having no toxic effects on the mouse body. This invention has extraordinary significance for T1B diabetes with impaired pancreatic cell function.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

Provided is a use of Staphylococcus lentus with an accession number of GDMCC 1.247 in preparation of a composition for preventing and treating insulin resistance or type 2 diabetes. This strain can significantly reduce the weight gain induced by a high-fat diet (HFD), improve the glucose tolerance, promote the insulin secretion, improve the insulin resistance, and significantly improve the immunity and inflammation.

The invention relates to application of insulin and analogues thereof in preparation of medicines for preventing or treating Alzheimer's disease. Researches find that the damage effect of A beta on insulin secretion depends on CX3CR1, the blood plasma insulin level of AD model mice can be recovered by supplementing exogenous insulin, and the A beta has the treatment effects of improving cognitive impairment of AD model mice, improving cerebrovascular lesion, recovering brain glycometabolism function, relieving brain inflammatory response and the like; the invention provides an alternative medicine with definite curative effect, high safety and affordable price for Alzheimer's disease, expands the indications of insulin and analogues thereof, and has wide market prospect and important social significance.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

Disclosed herein are compounds and ligands, and compositions formed therewith, that modulate insulin secretion and suppress appetite by activating ectopic olfactory receptors. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes, and disorders, such as abnormal insulin secretion.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

The invention provides a preparation process of mulberry, melon, fruit and vegetable protein paste for repairing islet cells and promoting insulin secretion, and relates to the technical field of hypoglycemic products. The prescription comprises a mulberry leaf extract, a bitter gourd extract, a white gourd extract, a cyclocarya paliurus extract, a sweet ampelopsis grossedentata extract, cucumbers, pumpkins, onions, corn stigma, lettuces, brassica juncea, asparagus, Chinese yams, radix puerariae, purple cabbages, broccoli, carrots, hericium erinaceus, black beans, white beans, zebra beans, hyacinth beans, cordyceps flowers, mushrooms, needle mushrooms, undaria pinnatifida, spirulina, leek seeds, lotus seeds, almonds, quinoa and spina date seeds. , chia seeds, pumpkin seeds, silkworm chrysalis and tenebrio molitor. The traditional Chinese medicine composition is prepared according to the traditional Chinese medicine theory and a scientific formula, and clinical verification shows that the traditional Chinese medicine composition has the effects of reducing blood sugar and blood fat, promoting digestion, invigorating the stomach, nourishing the liver and tonifying the kidney, can effectively improve and prevent diabetes mellitus, can also regulate gastrointestinal peristalsis and is helpful for regulating constipation. The prescription is simple to operate, low in cost and suitable for mass production.

The compositions and methods for improving or regulating GLP-1 levels, stimulating GLP-1 secretion, ameliorating metabolism including losing weight, managing glucose or insulin tolerance including stimulating insulin secretion, inhibiting glucagon secretion and reducing fasting glucose levels. The compositions comprise β-aminoisobutyric acid, a physiologically acceptable salt, polymer, ester, or 3-hydroxy-3-methylbutanoic acid, a physiologically acceptable salt, polymer, ester, or tributyrin or tributyrin derivative, or mixture thereof.

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

To provide a cell device that allows quicker induction of insulin secretion and suppression of insulin secretion from the initiation of operation, and also to provide a method for controlling insulin secretion.SOLUTION: A cell device 1 comprises: a culture vessel 2; a medium 3 and pancreatic β-cells 4 accommodated in the culture vessel 2; a working electrode 5, to which the pancreatic β-cells 4 adhere and which contains PEDOT:PzSS; a counter electrode 6 provided so as to be in contact with the medium 3; and a potential-application section 8 that applies a potential to the pancreatic β-cells 4 by means of the working electrode 5 and the counter electrode 6.SELECTED DRAWING: Figure 3

The invention discloses a stem cell medicine for pancreas islet repair and application, and belongs to the technical field of stem cell biology, and the stem cell medicine for pancreas islet repair is prepared by compounding a carrier, pancreatic progenitor cells and pancreas islet-like cells in proportion. The problems that in the prior art, due to the fact that stem cells are unstable in differentiation efficiency, poor in synergistic effect and poor in biocompatibility, islet injury cannot be repaired, and diabetes cannot be treated are solved. According to the present invention, the dual mechanisms of endogenous beta cell repair and exogenous beta cell supplement are adopted, and the beta cell function recovery and the group structure reconstruction are synchronously achieved through the reasonable ratio, such that the in-vivo blood glucose of the mouse is significantly reduced, the beta cell number and the glucose tolerance dose of the mouse are increased, and the low immunogenicity and the high anti-inflammatory property are simultaneously provided. The compound can be used for treating type I and type II diabetes mellitus, improving the insulin secretion function and relieving local inflammatory response of pancreas by promoting pancreas islet beta cell proliferation, and has application potential in treatment of type I and type II diabetes mellitus and pancreas islet repair.

The present invention relates to a composition comprising regulators / modulators of T1R2 / T1R3, T1R1 / T1R3, CaSR and GPRC6A affecting body metabolism. Moreover, the composition can assists in promoting early satiety sensation and optimizing insulin section during and / or after meals.

The application provides a construction method of a cell model for screening hypoglycemic drugs, and belongs to the technical field of biotechnology.The method provided by the application comprises the following steps: cell verification, vector construction and plasmid extraction, cell electroporation, drug screening, stable strain amplification and Q-PCR verification.The application successfully constructs a stable fluorescence reporter model (Min6-ins2>EGFP) based on Min6 cells, and verifies the specificity and sensitivity of the model to insulin secretion promoting drugs through positive drug verification.The model is simple to operate, can be monitored in real time, is suitable for high-throughput screening, can be effectively used for hypoglycemic activity evaluation of complex components such as chemical drugs and traditional Chinese medicines, and provides a reliable tool for early screening of hypoglycemic drugs.

The invention relates to an application of PBX1 as an active component in preparation of type 2 diabetes mellitus drugs or medical instruments, so as to relieve symptoms of diabetes mellitus, promote repair and regeneration of damaged pancreas islets and improve functions of insulin. The symptoms comprise water intake, food intake and fasting blood glucose; the method for promoting the repair and regeneration of the damaged pancreas islet comprises the steps of inhibiting the apoptosis of pancreas islet beta cells of diabetic mice, promoting the proliferation of the beta cells and recovering the tissue structure of the damaged pancreas islet; the function of improving the pancreas islet comprises the steps of stimulating secretion of insulin, improving the level of an insulin receptor, promoting absorption of an organism to glucose and reducing serum hyperglycemia and HbA1c concentration of diabetic mice, so that the effect of treating both symptoms and root causes of diabetes is achieved.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide XI (JZTX-XI) and application of Jingzhaotoxin polypeptide XI (JZTX-XI) in treatment of diabetes mellitus. A Jingzhaotoxin polypeptide XI coding gene, a nucleotide sequence of a 6 * His tag, a nucleotide sequence of a thrombin restriction enzyme cutting site and a nucleotide sequence of an MBP hydrotropy tag are connected to a prokaryotic expression vector for prokaryotic expression, and a target polypeptide which is high in purity, complete in disulfide bond folding and uniform in conformation is obtained through purification. The purity and the biological activity are relatively high. Meanwhile, the treatment activity of the JZTX-XI in the aspect of diabetes is verified, and it is found that the JZTX-XI can remarkably reduce fasting blood glucose of mice with type II diabetes, remarkably up-regulate a glucose transport regulation gene Glut2, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The present invention relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has the effects of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis and reducing triglyceride levels.

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and / or reversing, returning blood glucose concentration to a normal level in a diabetic.

The present invention belongs to the field of organoid culture technology, and specifically relates to a co-differentiated vascularized pancreatic islet organoid and a method for constructing the same. In view of the problems that the existing pancreatic islet organoid vascularization mostly adopts the co-culture method, which has a long operation process, is difficult, and has randomness and poor uniformity, the present invention provides a method for constructing a co-differentiated vascularized pancreatic islet organoid, which adopts human induced pluripotent stem cells hiPSCs, and sequentially induces and cultures them into directed endoderm cells, primitive intestinal tube cells and posterior foregut cells. In the subsequent induced differentiation, a culture medium containing VEGF, BMP4 and FGF2 is added for culture to obtain co-differentiated vascularized pancreatic islet organoid. For the first time, the present invention directs the differentiation of iPS cells to produce vascularized pancreatic islet organoids containing β, α, δ cells and vascular endothelial cells without adding exogenous endothelial cells. It is more mature than non-vascularized pancreatic islet organoids and has a stronger insulin secretion function, providing new ideas and experimental basis for achieving functional cure of diabetes.

To provide polypeptide-containing pharmaceutical compositions.SOLUTION: The invention relates to a pharmaceutical composition comprising a polypeptide, more specifically, a pharmaceutical composition for preventing or treating obesity, diabetes or non-alcoholic fatty liver disease. Th pharmaceutical composition is safe without any side effects such as nausea or vomiting with effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides. The invention relates to a polypeptide-containing pharmaceutical composition, medical use of the polypeptide-containing pharmaceutical composition, for example, use in treatment or prevention of obesity, diabetes or non-alcoholic fatty liver disease.SELECTED DRAWING: None

Provided are: an expression vector with which it is possible to create, in vivo in an animal, an insulin-producing cell directly in a live body and to produce an animal having insulin-producing tissue by a simple treatment, and which is useful for medical research; an insulin production model animal; a method for producing the insulin production model animal; and an insulin production method using the insulin production model animal. This expression vector has, with respect to a Tet control expression regulatory vector having a TRE3G promotor region, the MafA gene and the Pdx1 gene inserted on the upstream of the TRE3G promotor, and the Neurogenin3 gene and the Glis1 gene or a mutated Glis1 gene inserted on the downstream of the TRE3G promotor. The present invention also pertains to an insulin production model animal, a method for producing the insulin production model animal, and an insulin production method using the insulin production model animal.